Cargando…
Favipiravir: A new and emerging antiviral option in COVID-19
With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against th...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467067/ https://www.ncbi.nlm.nih.gov/pubmed/32895599 http://dx.doi.org/10.1016/j.mjafi.2020.08.004 |
_version_ | 1783577941098102784 |
---|---|
author | Agrawal, Umang Raju, Reyma Udwadia, Zarir F. |
author_facet | Agrawal, Umang Raju, Reyma Udwadia, Zarir F. |
author_sort | Agrawal, Umang |
collection | PubMed |
description | With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19. |
format | Online Article Text |
id | pubmed-7467067 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-74670672020-09-03 Favipiravir: A new and emerging antiviral option in COVID-19 Agrawal, Umang Raju, Reyma Udwadia, Zarir F. Med J Armed Forces India Review Article With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19. Elsevier 2020-10 2020-09-02 /pmc/articles/PMC7467067/ /pubmed/32895599 http://dx.doi.org/10.1016/j.mjafi.2020.08.004 Text en © 2020 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd. |
spellingShingle | Review Article Agrawal, Umang Raju, Reyma Udwadia, Zarir F. Favipiravir: A new and emerging antiviral option in COVID-19 |
title | Favipiravir: A new and emerging antiviral option in COVID-19 |
title_full | Favipiravir: A new and emerging antiviral option in COVID-19 |
title_fullStr | Favipiravir: A new and emerging antiviral option in COVID-19 |
title_full_unstemmed | Favipiravir: A new and emerging antiviral option in COVID-19 |
title_short | Favipiravir: A new and emerging antiviral option in COVID-19 |
title_sort | favipiravir: a new and emerging antiviral option in covid-19 |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467067/ https://www.ncbi.nlm.nih.gov/pubmed/32895599 http://dx.doi.org/10.1016/j.mjafi.2020.08.004 |
work_keys_str_mv | AT agrawalumang favipiraviranewandemergingantiviraloptionincovid19 AT rajureyma favipiraviranewandemergingantiviraloptionincovid19 AT udwadiazarirf favipiraviranewandemergingantiviraloptionincovid19 |